Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
This study is ongoing, but not recruiting participants.
Study NCT00940589   Information provided by Neurim Pharmaceuticals Ltd.

First Received on July 15, 2009.   Last Updated on April 15, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer's Disease
Sleep Disorder
Additional conditions recognized in this trial
Alzheimer Disease
Parasomnias
Sleep Disorders
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Tauopathies
Interventions listed in this trial
Circadin
Placebo
Additional drug interventions recognized in this trial
Cholinesterase Inhibitors
Melatonin
More general drug interventions related to this trial
Antioxidants
Central Nervous System Agents
Central Nervous System Depressants
Cholinergic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Neurim Pharmaceuticals Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services